Trans-Anal Minimally Invasive Surgery (TAMIS) for Completion Local Excision of Well-Differentiated Rectal Neuroendocrine Tumours. Abstract #1716

Introduction: Rectal NETs (R-NETs) <2cm are often amenable to endoscopic resection, but initial resections are often incomplete, and extended monitoring or radical surgery may then be required. Trans-anal minimally invasive surgery (TAMIS) allows resection of rectal tumours while reducing surgical morbidity. Data on its use in R-NETs is scant.
Aim(s): To assess the results of TAMIS for completion local excision of R-NETs following endoscopic resection.
Materials and methods: We reviewed patients undergoing TAMIS for NET at our institution (2013-2016). Included patients had incomplete endoscopic resection (margin ≤1mm), a visible scar on repeat endoscopy, and localized disease on systemic imaging. Full-thickness resection of the endoscopic scar was performed. Outcomes were 30-day major morbidity (Clavien-Dindo III-V), resection margin, and oncological outcomes.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Dr David Chan
Keywords: TAMIS

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1776 External Beam Radiotherapy (EBRT) in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review
Introduction: EBRT is infrequently used to treat GEPNETS.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Thompson R, Lam M, Pavlakis N, ...
Keywords: EBRT, review
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)
Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Victor Rodriguez-Freixinos
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#1350 Understanding a Neuroendocrine Tumors’ Impact on Health Systems: A Population-Based Economic Analysis of Patterns of Costs
Introduction: Little is known on resource utilization and health care costs in NET care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Hallet Julie
Authors: Hallet J, Law C, Cheung M, Fischer H, ...
Keywords: costs, care patterns